Livzon Pharmaceutical Group Inc. (SHE:000513)
China flag China · Delayed Price · Currency is CNY
26.41
-0.35 (-1.31%)
Aug 31, 2026, 3:04 PM CST

SHE:000513 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Net Income
1,6742,0232,0611,9541,9091,776
Depreciation & Amortization
574.19568.75575.14840.32652.32445.27
Other Amortization
57.0557.73144.5347.5833.3126.07
Loss (Gain) From Sale of Assets
3.593.21-38.142.0312.97-7.03
Asset Writedown & Restructuring Costs
72.2770.6712.80.570.166.15
Loss (Gain) From Sale of Investments
-120.15-58.14-12.27-37.4429.6-71.95
Provision & Write-off of Bad Debts
-2.38-0.54.6413.454.837.4
Other Operating Activities
440.86490.65419.62349.26204.44341.21
Change in Accounts Receivable
659.76-279.1270.24466.29-660.45-664.68
Change in Inventory
58.16398.57-13.32-334.42-498.57-232.01
Change in Accounts Payable
-137.51-58.99-388.51-115.711,035228.02
Change in Other Net Operating Assets
---3.3476.7347.3232.73
Operating Cash Flow
3,2213,1452,9793,2492,7731,902
Operating Cash Flow Growth
2.72%5.58%-8.31%17.18%45.75%-11.96%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Capital Expenditures
-392.11-574.14-570.16-820.45-940.15-1,309
Sale of Property, Plant & Equipment
1.41.991.5814.462.969.09
Cash Acquisitions
-1,680---22.46--
Divestitures
-----3.31
Investment in Securities
-1,713-1,360-103.05-1.59-399.18-675.7
Other Investing Activities
46.53-1,82911.3121.67106.595.5
Investing Cash Flow
-3,737-3,761-660.33-708.37-1,230-1,877

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Long-Term Debt Issued
-3,9105,8663,6583,7142,800
Total Debt Issued
5,3933,9105,8663,6583,7142,800
Long-Term Debt Repaid
--4,865-6,048-3,149-2,827-2,055
Net Debt Issued (Repaid)
-245.44-954.73-182.86508.29886.02744.96
Issuance of Common Stock
--208.55-42.25202.56
Repurchase of Common Stock
-193.41-579.87-858.56-346.15-56.04-238.18
Common Dividends Paid
-1,218-1,033-1,340-1,590-1,591-1,257
Other Financing Activities
-644.15-95.72-312.71-229.5-1.51-266.98
Financing Cash Flow
-2,301-2,663-2,486-1,657-720.36-815.02

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Foreign Exchange Rate Adjustments
-173.64-98.118.8120.04124.89-37.15
Net Cash Flow
-2,991-3,377-158.55903.72947.33-826.74

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Free Cash Flow
2,8292,5712,4092,4281,833593.23
Free Cash Flow Growth
15.51%6.73%-0.81%32.52%208.91%-60.81%
Free Cash Flow Margin
26.32%21.39%20.39%19.54%14.51%4.92%
Free Cash Flow Per Share
3.182.882.622.611.960.63
Levered Free Cash Flow
2,1081,7691,5861,694706.85-6.29
Unlevered Free Cash Flow
2,1381,8051,6411,758767.8146.21

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Cash Income Tax Paid
1,2711,3971,4541,3211,0251,236
Change in Working Capital
521.25-10.59-188.5679.51-74.36-620.46